Thumbnail
Access Restriction
Open

Author Yasutake, Toru ♦ Hidaka, Shigekazu ♦ Tanaka, Kenji ♦ Jibiki, Masa-aki ♦ Shibasaki, Shin-ichi ♦ Tsuji, Takashi ♦ Nanashima, Atsushi ♦ Sawai, Terumitsu ♦ Yamaguchi, Hiroyuki ♦ Nakagoe, Tohru ♦ Nagayasu, Takeshi
Source J-STAGE
Content type Text
Publisher Nagasaki University School of Medicine
Language English
Subject Keyword Gastrointestinal stromal tumor (GIST) ♦ Imatinib mesylate ♦ c-kit mutation ♦ Exon 11 ♦ Codon 551-557 ♦ Peritoneal metastasis
Abstract Gastrointestinal stromal tumors (GISTs) are common form of submucosal tumors of the stomach. Treatment of recurrent GISTs had been unsuccessful because of resistance to chemotherapy and radiotherapy. Recently, GISTs were reported to markedly respond to the molecular target agent, imatinib mesylate. We present here a patient with recurrent GIST and c-kit mutation who was successfully treated with imatinib mesylate. A 66-year-old man underwent partial gastrectomy because of GIST. The tumor was 3 cm in size and positive for KIT expression. One year after the excision, spiral computed tomography (CT) scan revealed four intra-peritoneal recurrence lesions measuring 7, 4, 3 and 2 cm in diameter. One week after the CT scan, we started treatment with imatinib mesylate at 400 mg/day, which resulted within two months in 40% decrease in the sum of the longest diameter. The reduction of tumor size continued for more than 6 months. Analysis of the c-kit mutation of the primary tumor revealed the deletion of 18 bases in exon 11 (codon 551-557), while other exons showed no mutation. In this report, we showed the effectiveness of imatinib mesylate therapy for the recurrence of GIST, especially with c-kit mutation in exon 11.
ISSN 00016055
Learning Resource Type Report
Publisher Date 2004-01-01
Journal Acta Medica Nagasakiensia(amn)
Volume Number 49
Issue Number 1+2
Page Count 4
Starting Page 63
Ending Page 66


Open content in new tab

   Open content in new tab